Dihydropyrrolopyridine inhibitors of RORγ
US10087184B2 · kind B2 · utility
10Cited by
29References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 20, 2017 |
| Grant date | Oct 2, 2018 |
| Priority date | — |
| Expiry date | Sep 20, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.